BioSpace News Archive

Duality Biotherapeutics, Inc. announced the appointment of Dr. Pasi A. Jänne as member of SAB.

China Pharma Holdings, Inc. announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 published by People’s Daily on December 12, 2022.

Gilgamesh Pharmaceuticals today announced the closing of a $39 million Series B round of financing.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein).

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January.

AnHeart Therapeutics announced today that the U.S. Food & Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to proceed with a global Phase 2 study of safusidenib for the treatment of patients with IDH1 mutant glioma.

Awakn Life Sciences Corp.(NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended October 31, 2022.

SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting.

Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.

Soligenix, Inc. announced today that it submitted a new drug application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for HyBryte™ (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer and area of unmet medical need affecting over 25,000 patients in the U.S.